196 related articles for article (PubMed ID: 18923451)
21. Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents.
Sors A; Jean-Louis F; Bégué E; Parmentier L; Dubertret L; Dreano M; Courtois G; Bachelez H; Michel L
Clin Cancer Res; 2008 Feb; 14(3):901-11. PubMed ID: 18245554
[TBL] [Abstract][Full Text] [Related]
22. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
[TBL] [Abstract][Full Text] [Related]
23. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis.
Nevala H; Karenko L; Vakeva L; Ranki A
Br J Dermatol; 2001 Dec; 145(6):928-37. PubMed ID: 11899146
[TBL] [Abstract][Full Text] [Related]
24. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
[TBL] [Abstract][Full Text] [Related]
25. Novel biomarkers, dysregulated epigenetics, and therapy in cutaneous T-cell lymphoma.
Wong HK
Discov Med; 2013 Sep; 16(87):71-8. PubMed ID: 23998443
[TBL] [Abstract][Full Text] [Related]
26. IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases.
Pham-Ledard A; Prochazkova-Carlotti M; Laharanne E; Vergier B; Jouary T; Beylot-Barry M; Merlio JP
J Invest Dermatol; 2010 Mar; 130(3):816-25. PubMed ID: 19812605
[TBL] [Abstract][Full Text] [Related]
27. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
28. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.
Litvinov IV; Cordeiro B; Fredholm S; Ødum N; Zargham H; Huang Y; Zhou Y; Pehr K; Kupper TS; Woetmann A; Sasseville D
Cell Cycle; 2014; 13(18):2975-82. PubMed ID: 25486484
[TBL] [Abstract][Full Text] [Related]
29. Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis.
Sors A; Jean-Louis F; Pellet C; Laroche L; Dubertret L; Courtois G; Bachelez H; Michel L
Blood; 2006 Mar; 107(6):2354-63. PubMed ID: 16219794
[TBL] [Abstract][Full Text] [Related]
30. Toll-like receptors 2, 4 and 9 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome).
Jarrousse V; Quereux G; Marques-Briand S; Knol AC; Khammari A; Dreno B
Eur J Dermatol; 2006; 16(6):636-41. PubMed ID: 17229603
[TBL] [Abstract][Full Text] [Related]
31. Decreased expression of Fas (APO-1/CD95) on peripheral blood CD4+ T lymphocytes in cutaneous T-cell lymphomas.
Dereure O; Portales P; Clot J; Guilhou JJ
Br J Dermatol; 2000 Dec; 143(6):1205-10. PubMed ID: 11122022
[TBL] [Abstract][Full Text] [Related]
32. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
33. Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL).
Wu J; Siddiqui J; Nihal M; Vonderheid EC; Wood GS
Arch Biochem Biophys; 2011 Apr; 508(2):185-91. PubMed ID: 21036138
[TBL] [Abstract][Full Text] [Related]
34. Reversible resistance to apoptosis in cutaneous T cell lymphoma.
Meech SJ; Edelson R; Walsh P; Norris DA; Duke RC
Ann N Y Acad Sci; 2001 Sep; 941():46-58. PubMed ID: 11594582
[TBL] [Abstract][Full Text] [Related]
35. A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma.
van Doorn R; Dijkman R; Vermeer MH; Starink TM; Willemze R; Tensen CP
Cancer Res; 2002 Oct; 62(19):5389-92. PubMed ID: 12359741
[TBL] [Abstract][Full Text] [Related]
36. Myocosis fungoides--an update on a non-mycotic disease.
Makdisi J; Friedman A
J Drugs Dermatol; 2013 Jul; 12(7):825-31. PubMed ID: 23884501
[TBL] [Abstract][Full Text] [Related]
37. Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells.
Kennah E; Ringrose A; Zhou LL; Esmailzadeh S; Qian H; Su MW; Zhou Y; Jiang X
Blood; 2009 May; 113(19):4646-55. PubMed ID: 19211505
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
39. T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL).
Bunn PA; Foss FM
J Cell Biochem Suppl; 1996; 24():12-23. PubMed ID: 8806090
[TBL] [Abstract][Full Text] [Related]
40. Expression of cancer/testis antigens in cutaneous T cell lymphomas.
Häffner AC; Tassis A; Zepter K; Storz M; Tureci O; Burg G; Nestle FO
Int J Cancer; 2002 Feb; 97(5):668-70. PubMed ID: 11807795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]